Insights and forecasts for the next wave of
Oncology breakthroughs

Oncology is entering a new era—where speed to market is no longer the ultimate prize, and success hinges on sustaining momentum with robust evidence, smart global trial design, and patient-centered innovation. From AI-driven drug discovery to regulatory reforms reshaping accelerated approvals, 2026 will test how well companies can align science, data, and market access strategies. In our latest Oncology Outlook, Lumanity’s experts unpack the trends, breakthroughs, and policy shifts set to redefine the competitive landscape—from transformative antibody-drug conjugates in triple-negative breast cancer to the growing role of real-world evidence in regulatory decision-making.

Stay ahead of the curve.

Download the full Oncology Outlook for 2026 whitepaper and gain deeper insights into the science, strategy, and market forces that will shape the next wave of cancer innovation.

Download the whitepaper

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Sign me up to receive regular insights from Lumanity
By selecting this box, I consent to receive Lumanity marketing communications by email.